Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department of Orthopedics, People's Hospital of Ningxiang City, Ningxiang, Hunan, China.
Front Immunol. 2022 Aug 1;13:896476. doi: 10.3389/fimmu.2022.896476. eCollection 2022.
To evaluate the randomized controlled trials (RCTs) of Curcumin and Curcuma longa Extract in the treatment of autoimmune diseases.
Databases such as Embase, Web of Science, PubMed and The Cochrane Library were searched from the database establishment to February 2022 to collect RCTs of Curcumin and Curcuma longa Extract in the treatment of autoimmune diseases. Then the literature was screened and the data were extracted. Meta-analysis was performed using RevMan 5.3 software.
A total of 34 records were included, involving 31 RCTs and 10 types of autoimmune disease. Among them, ankylosing spondylitis (AS) involves one RCT, Behcet 's disease (BD) involves one RCT, Crohn 's disease involves two RCTs, multiple sclerosis (MS) involves two RCTs, oral lichen planus involves six RCTs, psoriasis involves two RCTs, rheumatoid arthritis (RA) involves five RCTs, systemic lupus erythematosus (SLE) involves two RCTs, arteritis involves one RCT, ulcerative colitis (UC) involves nine RCTs. Among them, most of the RCTs of ulcerative colitis (UC), oral lichen planus, RA showed that curcumin and curcumin extracts improved clinical or laboratory results. Crohn ' s disease, MS, SLE, psoriasis included two RCTs; they all showed improvements (at least one RCT reported improvements in clinical outcomes). AS, BD and arteritis included only one RCT, and the clinical results showed improvement. However, due to the small number of RCTs and the small number of patients involved in each disease, there is still a need for more high-quality RCTs.
Curcumin and Curcuma longa Extract had good clinical efficacy in the treatment of Psoriasis, UC and RA, so Curcumin and Curcuma longa Extract could be used in the treatment of the above diseases in the future. The results of Meta-analysis showed that Curcumin and Curcuma longa Extract did not show efficacy in the treatment of oral lichen planus, while Takayasu arteritis, SLE, MS, AS, BD and CD did not report sufficient clinical data for meta-analysis. Therefore, large-sample, multi-center clinical trials are still needed for revision or validation.
评估姜黄素和姜黄提取物治疗自身免疫性疾病的随机对照试验（RCT）。
从建库至 2022 年 2 月，检索 Embase、Web of Science、PubMed 和 The Cochrane Library 等数据库，收集姜黄素和姜黄提取物治疗自身免疫性疾病的 RCT。然后筛选文献并提取数据。使用 RevMan 5.3 软件进行 Meta 分析。
共纳入 34 项研究，涉及 31 项 RCT 和 10 种自身免疫性疾病。其中，强直性脊柱炎（AS）涉及 1 项 RCT，白塞病（BD）涉及 1 项 RCT，克罗恩病（CD）涉及 2 项 RCT，多发性硬化症（MS）涉及 2 项 RCT，口腔扁平苔藓（OLP）涉及 6 项 RCT，银屑病涉及 2 项 RCT，类风湿关节炎（RA）涉及 5 项 RCT，系统性红斑狼疮（SLE）涉及 2 项 RCT，大动脉炎涉及 1 项 RCT，溃疡性结肠炎（UC）涉及 9 项 RCT。其中，UC、OLP、RA 的大多数 RCT 表明姜黄素和姜黄提取物改善了临床或实验室结果。CD、MS、SLE、银屑病包括 2 项 RCT，均显示改善（至少有 1 项 RCT 报告临床结局改善）。AS、BD 和大动脉炎仅包含 1 项 RCT，临床结果显示改善。但是，由于 RCT 数量较少，每种疾病涉及的患者数量较少，仍需要更多高质量的 RCT。
姜黄素和姜黄提取物在治疗银屑病、UC 和 RA 方面具有良好的临床疗效，因此姜黄素和姜黄提取物未来可用于治疗上述疾病。Meta 分析结果表明，姜黄素和姜黄提取物在治疗口腔扁平苔藓方面未显示出疗效，而大动脉炎、SLE、MS、AS、BD 和 CD 未报告足够的临床数据进行 Meta 分析。因此，仍需要进行大样本、多中心临床试验进行修订或验证。
Zotero 插件
